Quick Answer
Aptevo Therapeutics Inc. reported Operating Income of -$26.31 million for fiscal year 2025.
Aptevo Therapeutics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$26.31M | -7.0% |
| 2024 | -$24.60M | +14.8% |
| 2023 | -$28.88M | -0.8% |
| 2022 | -$28.64M | -33.8% |
| 2021 | -$21.40M | +22.2% |
| 2020 | -$27.49M | +32.9% |
| 2019 | -$40.96M | +20.7% |
| 2018 | -$51.66M | +4.2% |
| 2017 | -$53.95M | +61.1% |
| 2016 | -$138.77M | -127.1% |
| 2015 | -$61.10M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.61M | -46.0% | -22.2% |
| June 30, 2025 | -$6.23M | -3.4% | +3.9% |
| March 31, 2025 | -$6.48M | +7.2% | -24.3% |
| September 30, 2024 | -$5.21M | +20.5% | +13.5% |
| June 30, 2024 | -$6.02M | +26.3% | +13.7% |
| March 31, 2024 | -$6.98M | +10.0% | -6.4% |
| September 30, 2023 | -$6.56M | +15.7% | +19.8% |
| June 30, 2023 | -$8.18M | -8.1% | -5.4% |
- Aptevo Therapeutics Inc. showed a decrease of -7.0% in Operating Income compared to the prior fiscal year.
- Over the 2015–2025 period, Aptevo Therapeutics Inc.’s operating income has grown by 56.9% (from -$61.10 million to -$26.31 million).
- The most recent figure is from Aptevo Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: